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AbstrACt
Objectives Other than age, diabetes is the largest 
contributor to overall healthcare costs and reduced life 
expectancy in Europe. This paper aims to more exactly 
quantify the net impact of diabetes on different aspects of 
healthcare provision in hospitals in England, building on 
previous work that looked at the determinants of outcome 
in type 1 diabetes (T1DM) and type 2 diabetes (T2DM).
setting NHS Digital Hospital Episode Statistics (HES) in 
England was combined with the National Diabetes Audit 
(NDA) to provide the total number in practice of people 
with T1DM/T2DM.
Outcome measures We compared differences between 
T1DM/T2DM and non- diabetes individuals in relation to 
hospital activity and associated cost.
results The study captured 90% of hospital activity 
and £36 billion/year of hospital spend. The NDA Register 
showed that out of a total reported population of 58 million, 
2.9 million (6.5%) had T2DM and 240 000 (0.6%) had 
T1DM. Bed- day analysis showed 17% of beds are 
occupied by T2DM and 3% by T1DM. The overall cost 
of hospital care for people with diabetes is £5.5 billion/
year. Once the normally expected costs including the 
older age of T2DM hospital attenders are allowed for 
this fell to £3.0 billion/year or 8% of the total captured 
secondary care costs. This equates to £560/non- diabetes 
person compared with £3280/person with T1DM and 
£1686/person with T2DM. For people with diabetes, the 
net excess impact on non- elective/emergency work is 
£1.2 billion with additional estimated diabetes- related 
accident & emergency attendances at 440 000 costing 
the NHS £70 million/year. T1DM individuals required five 
times more secondary care support than non- diabetes 
individuals. T2DM individuals, even allowing for the age, 
require twice as much support as non- diabetes individuals.
Conclusions This analysis shows that additional cost 
of provision of hospital services due to their diabetes 
comorbidities is £3 billion above that for non- diabetes, 
and that within this, T1DM has three times as much cost 
impact as T2DM. We suggest that supporting patients in 
diabetes management may significantly reduce hospital 
activity.
INtrODUCtION
Other than age, diabetes is the largest contrib-
utor to overall healthcare costs and reduced 
life expectancy in Europe.1 People with type 1 
(T1DM) and type 2 (T2DM) diabetes require 
much higher levels of hospital support than 
their non- diabetes counterparts. Healthcare 
provision in hospital can be broken down 
into four main areas: (1) planned/elective 
including day- case admissions (Planned), (2) 
emergency/non- elective admissions (Emer-
gency), (3) accident & emergency (A&E) 
attendances and (4) outpatient consulta-
tions/attendances (Outpatient). Each of 
these different classes must be managed 
appropriately by clinicians and hospital 
administrators, and the relevance of diabetes 
to this planning may be different.
The National Diabetes Inpatient Audit2 has 
shown that 18% of all hospital beds on any 
1 day are occupied by people who have a diag-
nosis of diabetes2 compared with a 7% prev-
alence of all diabetes in the adult population 
of England. This may significantly overstate 
strengths and limitations of the study
 ► We were able to look at national level data across 
nearly 5500 general practitioner practices in relation 
to hospital activity. The analysis covered more than 
90% of hospital costs in England.
 ► Any conclusions drawn must account for the fact 
that our findings are based on association, not defi-
nite causation.
 ► Inherent in this real- world analysis methodology 
are potential confounding factors that are inherent 
in any retrospective study. Nevertheless, our design 
was such as to minimise the potential impact of 
such factors.
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the impact of the condition as over 90% of people with 
diabetes have T2DM, which generally occurs much later 
in life so that the cohort is significantly older than the 
general population—as such, their normal healthcare 
requirements would increase significantly with age.
NHS Digital publishes the general practitioner (GP) 
practice patient register split into age groups and can 
provide practice level extracts from Hospital Episode 
Statistics (HES) of the amount of different practice activi-
ties for people who have a recorded diagnosis of T1DM or 
T2DM and those that do not have such a diagnosis.3 The 
National Diabetes Audit (NDA) publishes the numbers 
and ages of people with either T1DM or T2DM in each 
practice4 also split into age groups. Other practice charac-
teristics such as ethnicity, social deprivation and location 
are also publicly available.5
The NHS in England publishes a significant amount 
of data at a GP practice level and we have previously 
described the impact of a variety of population, service 
and prescribing factors on outcomes.6 7 We have previ-
ously looked at the determinants of outcome in T1DM 
and T2DM in GP practices in England.6 7 It was felt that 
this approach could be used to quantify and so adjust for 
the effect of age on different services that are provided 
in hospital to T2DM individuals and therefore achieve 
a much more accurate evaluation of the actual net cost 
of diabetes, including all associated comorbidities to the 
health service.
AIMs
This paper aims to more exactly quantify the net impact 
of diabetes on the different aspects of healthcare provi-
sion in hospitals in England.
At GP practice level, we took the allocation of the 
different elements of hospital costs associated with the 
diagnosis of either T2DM or T1DM while adjusting for 
the difference in the T2DM age profile from the general 
population. We wished to use this analysis to provide a 
clearer focus for diabetes services to determine which 
elements of care they can focus on, in order to improve 
outcomes. Specifically, we compared differences between 
T1DM/T2DM and non- diabetes individuals in relation to 
hospital activity and the associated costs.
MEtHODs
Individual patients who had a diagnosis of either T1DM 
or T2DM and their age and practice code were identi-
fied within the NHS Digital HES data for 2016_2017 and 
2017_2018. The sum of annual activity of the different 
services, including emergency, elective, A&E and outpa-
tient care, was then extracted from the NHS Digital HES 
for each general practice for all those patients with a 
diagnosis of T1DM or T2DM and the non- diabetes indi-
viduals in 2017_2018. Emergency and elective activity 
were shown as totals for the number of unique patients, 
admissions, overall bed- days and the total national tariff 
charged, while only the number of unique patients and 
total attendances were provided for outpatient and A&E 
activity. The completeness of data was checked by looking 
at the national totals for the year reported within the 
reference costs.
The actual total population of T1DM and T2DM indi-
viduals and their age groups at the GP practice level was 
taken from NHS Digital NDA.4 Public Health England 
publishes the patient numbers and age profile of each GP 
practice from this total. The age profile for non- diabetes 
patients was calculated by subtracting the total diabetes 
population.
The demographic and location data for each practice 
including social deprivation, population density (urban/
rural), Latitude (Northerliness) were taken from the 
Office of National Statistics (ONS).5 The % minority 
ethnicity was also determined.
The total overall hospital costs for each practice in each 
of the three classes (T1DM, T2DM and non- diabetes) 
were calculated by adding the provided total elective and 
non- elective tariff charges to the Outpatient and Acci-
dent & Emergency attendances each multiplied by the 
national overall average cost/attendance taken from the 
2017–2018 national reference costs.
For each of the T1DM, T2DM and non- diabetes popu-
lation: Total Hospital Costs=Total recorded Elective Tariff 
Charges+Total recorded Non- Elective Tariff Charges+-
Total recorded Outpatient Attendances×Average annual 
Outpatient tariff cost/attendance+Total recorded Acci-
dent & Emergency attendances×average cost/attendance 
(both taken from the 2017–2018 national reference 
costs).
The number of practices included in the study was 
limited to those for which all the data sets were avail-
able plus if there were more than 200 T2DM patients or 
more than 20 T1DM patients on their register (5468 GP 
practices).
Practices that identify people earlier in the course of 
their T2DM increase their numbers and pro- rata this 
reduces the associated average hospital costs/person, to 
include for this a ‘T2DM %case identification’ factor was 
calculated. Our statistical model took account of this and 
linked the actual recorded T2DM register as % of the total 
practice population to the practice age, gender, ethnicity, 
social disadvantage, latitude and main long- term condi-
tion disease prevalence. Based on this statistical model, 
an expected level of T2DM could be predicted. The 
difference between the predicted and actual T2DM prev-
alence was taken as the local practice % case identifica-
tion. This factor was not required for T1DM as the onset 
of that condition is more clearly delineated, so all people 
with this condition can be more easily identified.
Patient and public involvement statement
It was not appropriate or possible to involve patients or 
the public in this work given that we used general prac-
tice level summated data and related hospital outcome 
statistics.
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Table 1 Data captured in study
2017_2018 Reference costs Extracted HES Captured
Organisation providing returns 152
Bed days 26 462 497 25 932 385 98%
Tariff charged £26 219 369 965 £19 392 269 892 74%
Outpatient attendance 87 714 235 119 758 272 137%
A&E attendances 19 950 458 20 737 416 104%
A&E, accident & emergency; HES, Hospital Episode Statistics.
statistics
A stepwise multiple regression model was created using 
Excel with Analyse- it add- in linking as outcome level of 
hospital activity of each class/head of population for 
T1DM and T2DM at GP practice level to the:
 ► The same measure for the non- diabetes population.
 ► % of non- diabetes population age >75.
 ► % of either T1DM or T2DM.
 ► % case identification (T2DM).
 ► Population density (pop/sq km)
 ► % black and minority ethnicity (BME).
 ► Practice size.
 ► % prevalence of T2DM.
 ► Latitude.
To remove the effect of the age difference between 
T2DM and non- diabetes population on the cost impact 
of diabetes, the regression coefficient was applied to the 
difference between % on patients over 75 in T2DM and 
the non- diabetes population, to give a ‘net’ T2DM disease 
impact on each of the activities and cost levels including:
 ► Overall costs.
 ► Emergency admissions, bed days and tariff.
 ► Elective admissions, day case, bed days and tariff.
 ► A&E attendances.
 ► Outpatient attendances.
To highlight the impact of the condition, the activity/
person for T1DM and T2DM was also shown as a ratio to 
the non- diabetes activity/person.
As diabetes can have many wide- ranging health impacts, 
establishing the overall additional all- cause hospital costs 
of diabetes on top of expected normal healthcare needs 
is difficult. Using a practice population- based approach 
allows us to allow for confounding factors such as age and 
disease identification. However, it remains a statistical 
analysis relying on large amounts of data entered during 
clinical treatments so it will contain normal administra-
tive errors. Nevertheless, it is hoped that both the scale 
of these data capturing over 160 million episodes and as 
these errors can be either over or under- reported that the 
outcomes should correspond to the actual values.
rEsULts
The study (see table 1) captured around 90% of the 
hospital activity data for England in 2017/2018. The 
missing 10% could be explained by the difference in 
definitions between the different analyses (ie, outpatient 
attendances and episodes which include more than one 
attendance). The tariff difference between the reference 
known costs of hospital T1DM/T2DM management and 
extracted HES of just under £7 billion could relate to 
other commercial costs or activities not captured within 
the HES data extraction.
The NDA Register showed that out of a total popula-
tion of 56 million in England, 2.9 million (6.5%) had 
T2DM and 270 000 (0.7%) had T1DM. The bed- day anal-
ysis confirmed that 17% of beds were occupied by T2DM 
and 3% by T1DM at a total of 20%, on average, of bed 
occupancy similar to that reported in the National Inpa-
tient Audit.2
The National average reference 2017_2018 costs/event 
for both consultant and non- consultant- led outpatient 
appointments is £125/attendance.8 The national average 
reference costs for the variety of A&E attendances 
including all the activities were £160/attendance.8
Included into the study (table 2) were practices for 
which there was enough data and to reduce the impact of 
single hander practice outliers and decrease the variance 
only practices with more than 200 T2DM patients were 
included in the estimation of age impact. This removed 
18% of practices and 6% of the T2DM population.
The results of the expected prevalence calculation are 
shown in figure 1. GP practices with a higher proportion 
of black and minority ethnicity (BME) ethnicity indi-
viduals, people with hypertension and coronary artery 
disease plus an older age profile had higher proportions 
of T2DM individuals. The statistical model based on these 
factors accounted for 74% of the variation in T2DM preva-
lence across GP practices in England. Higher proportions 
of BME individuals, individuals with a history of hyper-
tension, coronary artery disease and aged 65 or over have 
the strongest association with higher T2D prevalence. A 
‘T2DM Case Identification’ for each practice was then 
calculated from the actual prevalence of T2 divided by 
the expected value.
Figure 2A shows the age profile (proportion at a 
particular age) of non- diabetes, T1DM and T2DM in the 
England general population. For T2DM, the age distri-
bution is considerably different from the non- diabetes 
population, while the T1DM age distribution is close to 
the non- diabetes population. The figure also shows the 
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Table 2 Scope of study
2017_2018 Practices Population NDA T2 NDA T1
Total 7255 59 005 024 2 914 825 243 090
Complete data 6676 92% 55 924 632 95% 2 835 540 97% 236 025
T2>200 5468 75% 51 352 503 87% 2 656 850 91%
NDA, National Diabetes Audit .
Figure 1 T2DM identification. Statistical model linking % of 
T2DM to chosen practice factors. Factors contributing related 
to higher T2DM prevalence are on the right of the figure. 
BME, black and minority ethnicity; COPD, chronic obstructive 
pulmonary disease; GP, general practitioner; T2DM, type 2 
diabetes.
Figure 2 (A) Age distribution (proportion at a particular age) 
in the general population by diabetes type and proportion 
aged >65 years in hospital patients. (B) Impact in practices 
non- diabetes population of age% >75 years old on total 
hospital costs/non- diabetes population. GP, general 
practitioner; T1DM, type 1 diabetes; T2DM, type 2 diabetes .
proportion of over 65 within each of these diagnostic 
categories (T1DM, T2DM and non- diabetes) for hospital 
attendees. For hospital attendees, the proportion of 
admissions in the over 65 age for T2DM at 66% was much 
higher than for non- diabetes individuals at 22% and 
T1DM at 15%.
The age profile data showed that across all GP practices 
in England, for non- diabetes, 7% of people were aged 
>75 years, and for people with T2DM, 26% were age >75 
years old.
Figure 2B shows the variation of total hospital costs by 
the proportion of people on the GP list >75 years old. The 
univariate linear regression based on GP practice level 
total costs of hospital activity versus age profile of the 
practice shows that if 7% of people were aged >75 years 
in the GP practice, that the expected total non- diabetes 
population costs would be expected to be £568/person. 
However, if the figure was 26% of people aged >75 years, 
then the equivalent non- diabetes population costs would 
rise to £884/person. This univariant analysis suggests that 
the increased age of T2DM people accounts for up to 
£316/person of the cost difference.
Multivariate regression analysis for t2DM hospital costs
Figure 3A–3E shows the results from five of the multivar-
iate regression models used to link the level of cost and 
activity/T2DM person to the main drivers from the prac-
tice and levels for the non- diabetes populations including 
the age of both non- diabetes and T2DM%>75.
Overall hospital costs/various practice populations were 
normally distributed with skew and kurtosis factors for 
non- DM=0.06 and 1.7; T2DM=0.8 and 2.2 and T1DM=1.6 
and 2.7, mostly within the ±2 acceptable range.
The variation captured in each model was between 0.26 
and 0.63. The regression analysis shows that the main 
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Figure 3 (A–E) The results from five multivariate regression 
models linking to selected practice factors for T2DM- related 
hospital activity. A&E, accident & emergency; BME, black and 
minority ethnicity; T2DM, type 2 diabetes.
Figure 4 Comparison of hospital activity between non- diabetes and T1DM (split by the impact of population and condition) 
and T2DM (split by impact population, age, and condition). A&E, accident & emergency; T1DM, type 1 diabetes; T2DM, type 2 
diabetes.
driver for T2DM diabetes service costs and activity are as 
follows:
 ► Equivalent service costs for the non- diabetes 
population.
 ► Age%>75 of the T2DM population.
For the factors associated with lower T2DM hospital 
costs:
 ► Prevalence %T2DM.
 ► Age% >75 of the non- diabetes population.
 ► T2DM% case identification.
Minor factors that had variable effects included:
 ► Social deprivation.
 ► Practice size.
 ► T2DM prevalence.
 ► %BME ethnicity.
 ► Northerly latitude.
 ► Population density (urban/rural).
Similar patterns were seen across hospital total costs, 
non- elective costs, elective costs, outpatient total attend-
ances and A/E total attendances.
To extrapolate the level of the age effect contained 
within the T2DM activity and costs, the multiple regres-
sion coefficient for the proportion of T2DM individuals 
aged >75 years was taken for each measure from the anal-
ysis and applied to the difference between the T2DM 
value of 26% >75 years vs 7% of the non- diabetes popula-
tion >75 years old. The age- related impact on T2DM total 
acute costs difference/person is £300/person. This was 
similar to the £316 calculated by the univariant analysis.
Figure 4 highlights the relation of the diagnosis of 
T1DM and T2DM with the percentage of total hospital 
activity. While the numbers of T1DM are 0.42% and 
T2DM are 5.06% of the total background population, 
having allowed for the normal needs and influence of 
age, the net diabetes impact as a condition is 8.5% of 
hospital costs of the NHS (T1DM 1.8%+T2 DM 6.7%). 
In making up this net total, 13.9% are for emergency 
costs (T1DM 2.9%+T2 DM 11%), 9.2% are for elective 
costs (1.4% T1DM+7.8% T2DM), 6% are for outpatient 
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attendances (1.6%T1DM+4.4%T2 DM) and 2.2% are 
for A&E attendances (0.9% T1DM and 1.3% T2DM). 
Overall patients with diabetes are taking 19.3% of bed 
days, but after allowing for normal needs and age related, 
then the additional consumption is 11.9% of emergency 
beds (2.8%T1DM+9.1%T2 DM) and 5.4% elective beds 
(1.5%T1DM+3.9%T2 DM).
Table 3 provides an overview of the costs of diabetes 
including the impact of age on T2DM. £35.6 billion/
year of hospital spending is included in this analysis. This 
accounts for 66% of £53.7 billion total hospital income in 
England in 2017/2018, with the overall cost of hospital 
care for people with diabetes being £5.6 billion/year. 
Once the normally expected costs including the older 
age of T2DM, hospital attenders are allowed for this fell 
to £3.0 billion/year or 8% of the total captured secondary 
care costs. Of this, £0.65 billion or 21% of the age- 
adjusted diabetes spend came from the additional treat-
ment provided to T1DM individuals who were only 8% 
of the total diabetes population. This equates to £560/
non- diabetes person compared with £3280/person with 
T1DM and £1686/person with T2DM (of this £300 is 
associated with the age difference so the net impact on 
hospital costs is £826/person).
T1DM individuals required 5.9 times as much secondary 
care activity as non- diabetes individuals. For T2DM, 
having allowed for the age difference there is 2.5 times 
secondary care activity as non- diabetes individuals. The 
main area for these costs difference was the emergency/
non- elective care with 9.6 times the non- diabetes level for 
T1DM and 3.7 times non- diabetes level for T2DM. The 
elective treatment costs were 4.7 times for T1DM and 2.8 
times higher for T2DM than for non- diabetes.
total inpatient tariff charges
The total admission tariff charges for people with diabetes 
is £3.5 billion/year. £2.1 billion is for non- elective/emer-
gency and £1.4 billion elective work. Of this, £0.9 billion 
would be chargeable for average non- diabetes activity 
plus £0.6 billion can be associated with the older age of 
the T2DM. Therefore, the total net additional costs are 
£2 billion/year—this splits as £0.4 billion T1DM (£1620/
person) and £1.6 billion T2DM (£595/person).
For the non- diabetes population, non- elective/emer-
gency tariff charges are 46% of the total admission 
charges. For people with diabetes, the net excess impact 
on non- elective/emergency work is £1.2 billion or 60% 
of the total net excess; this splits as £3090/person T1DM 
and net £340/person/T2DM.
bed occupancy
The recorded 24.7 million bed days is equivalent to 67 577 
fully occupied beds; of these, 13 047 or 19.3% were taken 
by people with either T1DM or T2DM. Of these, 6858 
beds occupied (10%) can be explained by the expected 
health requirements of older age people. The remaining 
6183 (9.1% of total) can be considered a direct conse-
quence of the additional comorbidities associated with 
diabetes. Of these, 1645 (26% of DM excess total) excess 
beds are occupied by T1DM.
Closer examination of beds occupied by patients 
admitted in non- elective/emergency circumstances 
revealed that out of the total 38 914 fully occupied beds, 
8832 (22.6%) were occupied by people with diabetes, 
and allowing for the expected 4576 normal and older 
age, the excess in emergency is 4256 beds—these are 
11% of the total non- elective beds and 68% of the overall 
excess diabetes beds. It is also worth noting that 1174 of 
the excess non- elective beds are taken by T1DM people, 
making up 70% of the total 1645 T1DM excess beds.
Length of stay: excluding day cases
An average length of stay (LOS) for both elective over-
night and emergency admissions can be calculated by 
dividing their total bed days for both T1DM and T2DM 
(age- adjusted) by their total number of overnight admis-
sions for T1DM and T2DM (age- adjusted). These values 
can then be compared with the two different LOSs for the 
non- diabetes population.
The non- elective LOS for both T1DM and T2DM are 
only around 10% longer than non- diabetes, so most of 
the higher non- elective or emergency bed occupancy in 
diabetes must come from an increased rate of admission 
rather than LOS.
The elective LOS data are intriguing with the average 
overnight elective LOS for T1DM is at 1.0 day/person 
around 50% of the non- diabetes. For T2DM at 1.46 days/
person, LOS is 62% of the non- diabetes LOS. This 
suggests that these patients are receiving higher numbers 
of planned short overnight admissions across a number 
of specialities, to treat some of the consequences of their 
condition.
Elective day case
The evidence shows that elective day- case admissions 
for both T2DM (age- adjusted) and T1DM are around 
2.5 times the level of the non- diabetes patients. This will 
include day case podiatry procedures, ophthalmology 
and dialysis day- case attendances. This suggests that the 
increase in diabetes- associated comorbidities does also 
increase the amount of elective treatment levels that 
people with diabetes require.
Outpatient attendances
There was a big difference between the additional 
number of outpatient attendances that a person with 
T1DM patients showed at 4.8 times the non- diabetes 
attendances compared with the 1.8 times for T2DM. This 
might be due to the larger number of ongoing checks 
are being given to people with T1DM for eye, foot and 
renal complication management. The total additional 
outpatient attendances provided to people with diabetes 
to cover all the consequences of their condition was esti-
mated at 6.9 million or 6% of all outpatient attendances. 
At an estimated average reference cost of £125/atten-
dance, this costs the NHS total £825 million/year.
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A&E attendances
A&E attendances for T1DM were 3.1 times higher and 
T2DM 1.3 times higher than non- diabetes. The total 
additional estimated diabetes related A&E attendances at 
440 000 was 2% of all the A&E attendances in England in 
2017/2018. At an average cost of £160/attendance, this 
costs the NHS a total of £70 million/year.
DIsCUssION
There has been much discussion about the true cost 
of diabetes and its complications to the NHS. There 
is already significant investment in managing the 
3.2 million people identified with diabetes. The spend 
on glycaemic control medication alone in 2017_2018 was 
over £1 billion. This analysis shows that additional costs of 
provision of hospital services due to their diabetes comor-
bidities is £3 billion above those for non- diabetes and that 
within this T1DM have three times as much cost impact 
as T2DM. We have not included other forms of diabetes 
such as maturity onset diabetes of the young (MODY) 
or secondary diabetes in our analysis, as the numbers of 
people with these conditions are likely to be quite low at 
individual GP practices and coding of diagnosis is likely 
to vary.
In order to account for the variable rate of identifica-
tion of T2DM across GP practices, we have:
a. In the hospital data captured activity for all those pa-
tients whose hospital record as having diagnosis diabe-
tes at any visit during the previous 2 years.
b. In the practice data captured local total local popula-
tions having records of diabetes diagnosis.
c. In the latter, there will be an identification gap as prac-
tices will overdiagnose or underdiagnose compared 
with average. This gap will make those practices costs/
head relatively higher or lower and so we make it clear 
that some of these costs may be due to overdiagnosis/
underdiagnosis.
d. Also by calculating and bringing this identification gap 
into the age impact calculation, we remove this poten-
tial confounder from age impact.
In 2012, Hex et al9 in ‘Estimating the current and future 
costs of Type 1 and Type 2 diabetes in the UK, including 
direct health costs and indirect societal and productivity 
costs’ estimated the total secondary care costs at £7.7 billion 
with excess in- patient days at a cost £1.8 billion, of which 
99% was on T2DM. Marion Kerr in ‘Inpatient Care for 
People with Diabetes: The Economic Case for Change for 
Insight Health Economics’ November 201110 estimated 
the additional impact at £573 million–£686 million. 
Neither of these previous analyses took account of the 
age distribution difference between T2DM individuals 
and the non- diabetes population as we have done here.
Hex et al8 also indicated that less than 25% of that 
diabetes treatment cost relates to the costs of manage-
ment of diabetes, with the rest being accounted for by 
the costs of treating the complications of diabetes, which 
in one sense could be seen as ‘adverse events’. Another 
factor highlighted in this paper is that the indirect costs 
of diabetes are considerably higher than the direct costs 
and many relate to a cost to the individual with diabetes 
or to their carers. Cost estimates for productivity and 
social costs are often opportunity costs, such as time lost 
that could be spent on other activities.9 Furthermore, one 
quarter of care home residents in the UK have T2DM.11 
Access issues, where there are frailty and mobility prob-
lems preventing routine GP or hospital appointment 
visits, can result in services being quite variable in delivery 
from one area to another.12
An International Diabetes Federation study13 showed 
that people with diabetes have medical costs that are two 
to three times more than age- matched and sex- matched 
patients without diabetes, that is, that if the average 
healthcare cost per person without diabetes is $1000 
(£787), for a similar person with diabetes the cost will 
be $2000-$3000. These figures are not dissimilar to those 
reported in our study—of £560/non- diabetes person 
compared with £1810/person with diabetes. The signif-
icant excess of non- elective and elective activity and costs 
for T1DM individuals is indicative of the complexities 
of management of this condition and is related to the 
fact that many people with T1DM do not achieve target 
glycaemic control with hypoglycaemia, a frequent cause 
of hospital A/E attendance.14
There is also large pressure on hospital beds and espe-
cially with emergency admissions. That 11% of emergency 
beds are occupied by patients being admitted through 
the direct consequences their diabetes and 27% of these 
are T1DM shows that supporting patients in managing 
their diabetes remains a clear focus for primary care 
with T1DM remaining a very important aspect. LOS as 
reported here is also a factor and this can be impacted 
significantly by effective deployment of diabetes specialist 
nurses on wards.15
The total additional outpatient attendances provided 
to people with diabetes to cover all the consequences 
of their condition was estimated at 6.9 million or 6% 
of all outpatient attendances. This might be due to the 
larger number of ongoing checks that are being given to 
people with T1DM for eye, foot and renal complication 
management and to many people with T1DM. This also 
highlights a possible opportunity to deliver more of these 
services in the community rather than in the hospital for 
these patients.
The higher number of elective day- case, elective and 
A/E attendances likely are a consequence of manage-
ment of diabetes complications and comorbidities in 
both T1DM and T2DM.
We acknowledge that we have not analysed ways in 
which the hospital costs of diabetes could be reduced. We 
know that people with diabetes are constantly managing 
their condition on a daily basis but may only come into 
contact with healthcare professionals a couple of times a 
year. Therefore, education programmes that give people 
the knowledge and motivation to manage their condi-
tion have value. For people with T1DM, Dose Adjustment 
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Normal Eating (DAFNE)16 is an education course that 
trains people to estimate the carbohydrate in each meal 
and to inject the right dose of insulin. A cost- effectiveness 
analysis17 based on economic data from randomised 
control trials on DAFNE and similar programmes in 
Germany and Austria shows very good results. A 7- year 
follow- up on UK patients who went on a DAFNE course 
showed that their glycaemic control remained better than 
a similar group who had not been on the course.18 Over 
10 years, structured treatment and teaching programmes 
save £2200 per patient. The majority of the savings arose 
from avoiding dialysis and foot ulceration.
Education for people with T2DM is also cost- effective. 
Data from a leading education programme, X- PERT, 
show the costs are outweighed by savings in cardiovas-
cular and diabetes medication.19 A systematic review rated 
X- PERT as very cost- effective.20 Another major education 
programme, Diabetes Education and Self Management 
for Ongoing and Newly Diagnosed (DESMOND),21 is also 
effective with the key benefits being reductions in weight 
and smoking rate.22
In our recent papers,6 7 we showed that access to expert 
patient programmes can result in significant improve-
ments in glycaemia control as can informed choice of 
diabetes medication. If achieved, such improvements in 
glycaemia could have the potential to reduce hospital 
costs in the longer term.
Healthcare systems influence a broad range of treat-
ment decisions, both directly, via implemented policies/
guidelines, and indirectly through the impact of shorter 
duration of clinical appointments and patients’ percep-
tions of their healthcare needs. We hope that this paper 
will be helpful to those who direct policy in healthcare 
both in the UK and elsewhere in the world.
CONCLUsION
People with diabetes have a significant impact on hospital 
activity including management of diabetes- related 
complications. They are admitted more often especially 
as emergencies and stay on average for longer. People 
with T1DM, although 10% of the people with diabetes 
have more than threefold the impact of T2DM, so require 
more special attention. However, people with T2DM 
have a wider range of comorbidities and so can be more 
complex.
While not a conclusion that we can draw directly from 
our analysis, it is possible that improved management 
of T1DM and T2DM in primary care in terms partic-
ularly of measures to prevent the longer term develop-
ment of complications may reduce the level of hospital 
activity and hospital costs. The role of the secondary care 
specialist team in supporting primary care and ensuring 
that most people with diabetes are being well managed, 
not just focussing on the smaller in number hardest to 
treat group will be a key factor in improving primary care 
management outcomes will be critical in this endeavour.
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